Corcept Therapeutics Incorporated (CORT)
Operating profit margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Operating income | US$ in thousands | 136,951 | 107,282 | 112,634 | 124,477 | 128,202 |
Revenue | US$ in thousands | 675,040 | 482,375 | 401,858 | 365,978 | 353,874 |
Operating profit margin | 20.29% | 22.24% | 28.03% | 34.01% | 36.23% |
December 31, 2024 calculation
Operating profit margin = Operating income ÷ Revenue
= $136,951K ÷ $675,040K
= 20.29%
The operating profit margin of Corcept Therapeutics Incorporated has shown a declining trend over the past five years. Starting at 36.23% on December 31, 2020, the margin decreased to 20.29% by December 31, 2024. This downward trend indicates that the company's operating efficiency in generating profits from its core business operations has decreased over time. It is essential for the company to closely monitor its operating expenses and revenue generation strategies to potentially reverse this trend and improve profitability in the future.
Peer comparison
Dec 31, 2024
Company name
Symbol
Operating profit margin
Corcept Therapeutics Incorporated
CORT
20.29%
Abbott Laboratories
ABT
16.27%
AbbVie Inc
ABBV
16.22%
ACADIA Pharmaceuticals Inc
ACAD
24.10%
Alkermes Plc
ALKS
27.02%
Amphastar P
AMPH
28.06%
ANI Pharmaceuticals Inc
ANIP
0.10%
Arcus Biosciences Inc
RCUS
-127.91%
Biomarin Pharmaceutical Inc
BMRN
17.02%
Bristol-Myers Squibb Company
BMY
-25.99%
Catalyst Pharmaceuticals Inc
CPRX
39.68%